Design and Clinical Evaluation of a School Meal With Deworming Properties

Sponsor
Kenya Medical Research Institute (Other)
Overall Status
Completed
CT.gov ID
NCT02725255
Collaborator
United States Agency for International Development (USAID) (U.S. Fed), Bill and Melinda Gates Foundation (Other)
326
3
10

Study Details

Study Description

Brief Summary

Intestinal parasites (IP) are among the world's neglected tropical diseases. Morbidity due to IPs is greatest in school-age children who typically have the highest burden of infection. In 2001, WHO passed a resolution for the use of large-scale mass drug administration (MDA) of antihelminthic drugs to deworm children in developing countries. Though initially effective, there is concern that MDA might not be sustainable over extended periods especially considering the large children populations and the high frequency of dosing. Further, the MDAs exert increasing drug pressure on parasite populations, a circumstance that is likely to favor parasite genotypes that can resist anthelmintic drugs. There is hence a need for alternatives that are not only affordable and sustainable but easier to implement in the long term with a minimal chance of development of resistance. The investigators propose to develop and test the feasibility of a corn porridge meal fortified with papaya fruit extracts that have been shown to have antihelminthic properties. The investigators intend to evaluate its efficacy when given through school feeding programs and compare the outcome with albendazole- the recommended MDA agent for deworming school children. The investigators will design and formulate the product and test it among children in three primary schools in Western Kenya.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Detailed Description

Background: Soil transmitted helminthes (STHs) are among the world's neglected tropical diseases. Morbidity due to STHs is greatest in school-age children who typically have the highest burden of infection. In 2001, WHO passed a resolution for the use of large-scale mass drug administration (MDA) to deworm vulnerable children. Though effective, there is concern that MDA might not be sustainable over extended periods. Additionally the current MDA strategy do not consider child malnutrition, a very common malady in resource limited countries. The investigators report a pilot evaluation of an innovation that bundles school feeding and deworming.

The investigators designed a maize (corn) flour fortified with grounded dried papaya (Carica papaya) seeds and used it to prepare porridge as per the usual school meal recipe. Children from three primary schools from Nandi County in Kenya were randomized into three arms: One school received 300 ml papaya fortified porridge daily (test school), a second school received similar serving of plain porridge without the pawpaw ingredient (placebo) and a third school received the placebo porridge and the conventional MDA approach of one time 400mg dosage of albendazole. Prior to the randomization, an initial baseline stool microscopy analysis was done to determine presence and intensity of intestinal worms. Core indicators of nutrition-height, weight and hemoglobin counts-were also assessed. The children were monitored daily for two months and final stool sample analysis and clinical monitoring done at the end of the study. Baseline and follow-up data were analyzed and compared through SAS version 9.1 statistical package.

Study Design

Study Type:
Interventional
Actual Enrollment :
326 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Design and Clinical Evaluation of a School Meal With Deworming Properties
Study Start Date :
May 1, 2015
Actual Primary Completion Date :
Nov 1, 2015
Actual Study Completion Date :
Mar 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Papaya seed porridge

Arm receiving porridge fortified with dried papaya seeds (Ujiplus)

Dietary Supplement: Ujiplus
Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.

Active Comparator: Albendazole and Plain porridge

Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)

Drug: Albendazole
400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
Other Names:
  • Albenza
  • Placebo Comparator: Plain porridge

    arm receiving 300ml plain porridge daily (without papaya seeds)

    Dietary Supplement: uji
    maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.

    Outcome Measures

    Primary Outcome Measures

    1. parasite egg count [60 days after randomization]

      ova and cyst counts of various helminths in stool sample at end of intervention

    Secondary Outcome Measures

    1. Body Mass Index for age [60 days after intervention]

      Height, Weight and age were collected. BMI was calculated using WHO guidelines.

    2. school attendance [60 days after randomization]

      school register used to gather information of attendance, enrollment and retention of students

    3. haemoglobin levels [baseline and after 60 days]

      blood sample is taken for hemoglobin amounts at start and end of intervention

    4. Number of children with tinea capitis [60 days after randomization]

      Number of children with tinea capitis (ringworms) 60 days after randomization

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    4 Years to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Consenting parents and guardians
    Exclusion Criteria:
    • children with known allergy to papaya fruit products

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Kenya Medical Research Institute
    • United States Agency for International Development (USAID)
    • Bill and Melinda Gates Foundation

    Investigators

    • Principal Investigator: Elijah M Songok, PhD, Kenya Medical Research Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Elijah M. Songok, Prof. Elijah M. Songok, Kenya Medical Research Institute
    ClinicalTrials.gov Identifier:
    NCT02725255
    Other Study ID Numbers:
    • SSC2580
    First Posted:
    Mar 31, 2016
    Last Update Posted:
    Sep 7, 2016
    Last Verified:
    Sep 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 7, 2016